- Poster presentation
- Open Access
Design and synthesis of the first NO- and haem-independent sGC activator BAY 58–2667 for the treatment of acute decompensated heart failure
© Hahn et al; licensee BioMed Central Ltd. 2007
- Published: 25 July 2007
- Nitric Oxide
- Chronic Heart Failure
- High Throughput Screening
- Guanylate Cyclase
- Haemodynamic Effect
Soluble guanylate cyclase (sGC) is a signal-transduction enzyme activated by nitric oxide (NO) and plays a key role in a variety of physiological processes such as vasodilatation, antiaggregation, antiproliferation and neuronal signaling as well as in a variety of disorders of these functions. Current therapies that involve the use of organic nitrates and other NO donors have limitations, including non-specific interactions of NO with various biomolecules and lack of response and the development of tolerance [1, 2]. Compounds that activate sGC in an NO-independent manner might therefore provide considerable therapeutic advantages.
- Stasch JP, Schmidt P, Alonso-Alija C, Apeler H, Dembowsky K, Haerter M, Heil M, Minuth T, Perzborn E, Pleiss U, Schramm M, Schroeder W, Schröder H, Stahl E, Steinke W, Wunder F: NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle. Br J Pharmacol. 2002, 136: 773-783. 10.1038/sj.bjp.0704778.PubMed CentralView ArticlePubMedGoogle Scholar
- Evgenov OV, Pacher P, Schmidt PM, Haskó G, Schmidt HHHW, Stasch JP: NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nature Reviews Drug Discovery. 2006, 5: 755-768. 10.1038/nrd2038.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd.